1,447 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Roche's Lung Cancer Drug Alecensa Meets Primary Endpoint http://www.zacks.com/stock/news/255925/roches-lung-cancer-drug-alecensa-meets-primary-endpoint?cid=CS-ZC-FT-255925 Apr 10, 2017 - Roche (RHHBY) announced that the global, randomized phase III study, ALEX, on lung cancer drug Alecensa met its primary endpoint as an initial (first-line) treatment.
Nepsis Capital Management, Inc. Buys STMicroelectronics NV, Cisco Systems, ArcelorMittal SA, ... http://www.gurufocus.com/news/500926/nepsis-capital-management-inc-buys-stmicroelectronics-nv-cisco-systems-arcelormittal-sa-sells-nutanix-walmart-stores-ventas Apr 07, 2017 - Nepsis Capital Management, Inc. Buys STMicroelectronics NV, Cisco Systems, ArcelorMittal SA, Sells Nutanix, Wal-Mart Stores, Ventas, Stocks: RIO,FFIV,STM,CSCO,MT,TWLO,CHKP,AXS,NTNX,WMT,AIRG,, release date:Apr 07, 2017
Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK? http://www.zacks.com/stock/news/254783/pharma-stock-roundup-fda-nod-for-sny-roche-drugs-generic-advair-relief-for-gsk?cid=CS-ZC-FT-254783 Mar 31, 2017 - Two drugs with blockbuster potential - Sanofi (SNY)/Regeneron's Dupixent and Roche's Ocrevus - gained FDA approval this week.
Novartis' CTL109 BLA Gets Priority Review Status from FDA http://www.zacks.com/stock/news/254719/novartis-ctl109-bla-gets-priority-review-status-from-fda?cid=CS-ZC-FT-254719 Mar 30, 2017 - Novartis A.G. (NVS) announced that the FDA has accepted and granted priority review designation to its biologics license application (BLA) for pipeline candidate, CTL019 (tisagenlecleucel-T).
AEGON NV: It's Closing Time For This Preferred Stock https://seekingalpha.com/article/4058629-aegon-nv-closing-time-preferred-stock?source=feed_sector_financial Mar 28, 2017 - AEB has reached levels where the upside potential is limited by its fundamentals.Floating Rate preferred stocks have had a good year so far, but at some point it is wise to cash in.There are other opt
Leucadia National Buys Lonestar Resources US, NXP Semiconductors NV, Deutsche Bank AG, Sells ... http://www.gurufocus.com/news/495759/leucadia-national-buys-lonestar-resources-us-nxp-semiconductors-nv-deutsche-bank-ag-sells-procter--gamble-co-coty-spdr-sp-500 Mar 27, 2017 - Leucadia National Buys Lonestar Resources US, NXP Semiconductors NV, Deutsche Bank AG, Sells Procter & Gamble Co, Coty, SPDR S&P 500, Stocks: LONE,NXPI,DB,LVLT,JNS,TLT,SINA,SPY,WR,PG,COTY,GLD,, release date:Mar 27, 2017
J&J (JNJ) Anaemia Drug Marketing Label Expanded in Europe http://www.zacks.com/stock/news/254220/jj-jnj-anaemia-drug-marketing-label-expanded-in-europe?cid=CS-ZC-FT-254220 Mar 27, 2017 - Johnson & Johnson (JNJ) announced that the French health authority has granted approval to expand the label of Eprex to include treatment of symptomatic anaemia in patients with low or intermediate risk myelodysplastic syndromes (MDS).
TiGenix NV (ADS) (TIG) Presents At Deutsche Bank Depositary Receipts Virtual Investor Conference - Slideshow https://seekingalpha.com/article/4057764-tigenix-nv-ads-tig-presents-deutsche-bank-depositary-receipts-virtual-investor-conference?source=feed_sector_healthcare Mar 24, 2017 - The following slide deck was published by TiGenix NV (NYSE:ADS) in conjunction with this event.
The Zacks Analyst Blog Highlights: Milacron Holdings, Galapagos NV and Raymond James Financial http://www.zacks.com/stock/news/254054/the-zacks-analyst-blog-highlights-milacron-holdings-galapagos-nv-and-raymond-james-financial?cid=CS-ZC-FT-254054 Mar 24, 2017 - The Zacks Analyst Blog Highlights: Milacron Holdings, Galapagos NV and Raymond James Financial
Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved http://www.zacks.com/stock/news/253983/pharma-stock-roundup-is-sanofi-buying-flexion-pfizer-merck-kgaa-drug-approved?cid=CS-ZC-FT-253983 Mar 24, 2017 - This week's highlights include rumors regarding Sanofi (SNY) acquiring Flexion, accelerated FDA approval for a Pfizer/Merck KGaA drug and drug pricing.
<<<Page 134>